PEP/NEWS — Peptide intel. Daily.

If you're confused by all the hype around MUSE stem cells and wondering where they actually come from, this video is for you. I explain what MUSE cells are, how they were discovered in Japan, what makes them different from other stem cells,

Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer’s disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer’s dis

Get LMNT Electrolytes & Receive a FREE Sample Flavors Pack: http://drinklmnt.com/thomas Follow Dorian on Instagram: https://www.instagram.com/thedorianyates/ Dorian's Nutrition Company, DY Nutrition: https://dynutrition.com/en-us This vid

Peter Attia's AMA #86 tackles the GLP-1 receptor agonist and muscle loss debate head-on. He reviews new data showing that patients who hit protein targets and do resistance training lose very little lean mass. The episode is a practical counterweight to the blanket concern that GLP-1 drugs are muscle-wasting agents.

Attia's AMA #71 rebroadcast covers how to build muscle and strength for long-term health. He argues that movement volume is the single strongest predictor of longevity. Training and nutrition guidance is framed entirely around lifespan extension, not aesthetics.

Sarcopenia (age-related muscle loss) and osteoporosis (age-related bone loss) share more biology than previously understood. Researchers mapped cross-talk between muscle and bone signaling that accelerates both when either begins to fail. This has direct implications for peptides studied in the musculoskeletal space.

Venture capital into biotech hit its highest first-half total since early 2022. The catch: capital is concentrating in large platform bets. Smaller peptide-focused startups are being passed over as investors chase late-stage assets with clearer regulatory paths.

Bryan Johnson outlines four cardiovascular protocols tied to his published biomarker results. His blood pressure reportedly tests lower than 90% of 18-year-olds. The piece is useful context for researchers tracking lifestyle variables alongside peptide interventions.

ARPA-H is committing $160 million to build a roadmap for personalized gene-editing drugs. The funding framework could eventually apply to bespoke peptide-based therapeutics. Separately, a Botox rival showed efficacy against migraines in a new readout.

Researchers used spatial mapping to locate senescent and disease-linked microglia (the brain's immune cells) in aged white matter. They then applied senolytic targeting to clear these cells. The work opens a path for more precise brain-directed senolytic strategies.

A Nature Aging study found that trained human muscle shows delayed molecular aging and better energy metabolism. Some age-related molecular changes resist exercise — identifying what exercise cannot fix may be where peptide interventions matter most.

Centenarians carrying specific SIRT6 gene variants accumulate fewer senescent cells over a lifetime. The finding helps explain why some people age slowly without intervention. It also suggests SIRT6 as a target for compounds — including peptides — aimed at reducing senescent cell burden.

Part one of a three-part deep dive covers how cancer starts at the cellular level and which signaling pathways tumors exploit. It sets the foundation for understanding where peptides fit — and where they pose risk — in oncology contexts.